Researchers report a subset of monocytes releases interleukin-10 (IL-10), a molecule that helps switch off pain. They found these IL-10-producing cells were more active in males. The difference was linked to higher sex hormones such as testosterone.
Women in the study experienced longer-lasting pain and slower recovery because their monocytes were less active. The pattern appeared in both mouse models and human patients. A separate study after car accidents showed similar results.
The team says immune cells could be encouraged to make more calming signals. A new treatment is likely decades away, but researchers hope this work will lead to non-opioid options and make doctors take women's pain seriously.
Difficult words
- monocyte — a type of white blood cell in the immune systemmonocytes
- interleukin-10 — a molecule made by immune cells that reduces painIL-10
- testosterone — a male sex hormone in the human body
- recovery — the process of getting better after illness or injury
- subset — a small group taken from a larger group
- immune — relating to the body's defence against disease
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Have you or someone you know had long-lasting pain? What happened?
- What can doctors do to take women's pain more seriously?
- Would you prefer a non-opioid treatment for pain? Why or why not?
Related articles
New oral drug approved for sleeping sickness
European regulators approved Acoziborole, a single-dose oral treatment for sleeping sickness after successful trials in the DRC and Guinea. Sanofi will donate doses to WHO, but national approvals and vector control are still needed to reach elimination goals.
Climate shocks, crop losses and health risks in Africa
Climate shocks in parts of Africa are hurting crops and helping pests and mosquitoes spread. Farmers face failed harvests and public health risks like malaria and cholera, while experts call for better infrastructure and funding.
Lower chemotherapy dose helps people 80+ with lymphoma
A study found that people aged 80 and older with a common lymphoma often do better with a lower chemotherapy dose. Researchers used data from community cancer clinics and say the smaller dose kept effectiveness while reducing side effects.
Study finds many “clean” products for textured hair still risky
A new study examined 150 hair products labeled “Target Clean” from a Target store in South Los Angeles. Researchers compared ingredient lists with the EWG database and found many products still pose moderate health hazards.